ArticleAnnals of translational medicine2021
Hyperuricemia prevalence and its association with metabolic disorders: a multicenter retrospective real-world study in China.
Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials.BMC pharmacology & toxicology · 2023Pooled it
- Prevalence of Diabetes in Patients with Hyperuricemia and Gout: A Systematic Review and Meta-analysis.Current diabetes reports · 2023Pooled it
- Effects of Xanthine Oxidase Inhibition by Febuxostat on Lipid Profiles of Patients with Hyperuricemia: Insights from Randomized PRIZE Study.Nutrients · 2024Trial
- Interactions between serum uric acid and gut microbiota: implications for metabolic health.Metabolism open · 2026Review
- Drug-induced hyperuricemia: multi-pathway regulation, causative drugs, and individualized management strategies.Frontiers in pharmacology · 2026Review
- Hyperuricemia Is Independently Associated With Hyperlipidemia in a Large Population-Based Study.Journal of clinical laboratory analysis · 2025Article
- Risk factors for early-onset hyperuricemia and gout following laparoscopic sleeve gastrectomy: a retrospective study.BMC surgery · 2025Article
- The prevalence and risk factors of hyperuricemia in patients with Newly-diagnosed coronary artery disease from 2017 to 2021.BMC cardiovascular disorders · 2025Article
- Article
- Article
- Correlation of the lipid complex marker hs-CRP/HDL-C ratio with hyperuricaemia: a cross-sectional retrospective study from NHANES 2015-2018.Scientific reports · 2025Article
- The dose-response relationship and gender differences of serum uric acid with total cholesterol: a cross-sectional study.The Journal of international medical research · 2025Article
- Nonlinear association between triglyceride-glucose index and risk of hyperuricemia in early-stage cardiovascular-kidney-metabolic syndrome: a cross-sectional study of United States population.Frontiers in cardiovascular medicine · 2025Article
- The Burden of Multiple Metabolic Diseases and Their Impact on Cardiovascular and Kidney Complications in Type 2 Diabetes: A 10-Year Real-World Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Plantaginis Semen Ameliorates Hyperuricemia Induced by Potassium Oxonate.International journal of molecular sciences · 2024Article
- Anti-hyperuricemia effect of Clerodendranthus spicatus: a molecular biology study combined with metabolomics.Scientific reports · 2024Article
- Ameliorative action of "daitongxiao" against hyperuricemia includes the "uric acid transporter group".Frontiers in pharmacology · 2024Article
- Insulin Resistance Surrogates May Predict HTN-HUA in Young, Non-Obese Individuals.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial.The Lancet regional health. Western Pacific · 2023Article
- Associations of serum uric acid with cardiovascular disease risk factors: a retrospective cohort study in southeastern China.BMJ open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of hyperuricemia (HUA) and gout continues to increase in China. Research suggests that HUA may be related to many diseases other than gout. However, further population research is required to investigate the association between HUA and metabolic syndromes. This study sought to investigate the prevalence of HUA in an average population in China, and the association between serum uric acid (UA) levels and related metabolic disorders.
methodsThis multicenter retrospective real-world study examined the hospital information system data of 4 tertiary hospitals in 3 provinces in China. The data of patients aged between 18 and 80 years, who had attended at least 1 medical appointment at which their UA level was recorded, were analyzed to evaluate associations between UA levels and metabolic disorders.
resultsAmong the 374,506 enrolled subjects (49.7% male; mean age 51.5 years old), the overall prevalence of HUA and gout were 14.8% and 0.5%, respectively. The prevalence was higher among males than females (17.6%
conclusionsHUA is associated with dyslipidemia and CKD both cross-sectionally and longitudinally. Similar phenomena were observed in both sexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.